Biovian and 3P Biopharmaceuticals (“3P”), two leading biologics Contract Development and Manufacturing Organizations (CDMOs), announced today their combination to establish a new pan-European leader in their field. Backed by their common shareholder, Keensight Capital, one …
Biovian is excited to announce participation in two major industry events to start 2024. Our representatives are ready to meet you at the Advanced Therapy Week 2024 in Miami and PepTalk 2024 in San Diego, …
Biovian is delighted to announce the successful completion of a debt refinancing initiative and securing a new funding package with Eurazeo, a French investment company, to support GeneCity facility expansion. The package will be used …
We are delighted to announce that Magnus Gustafsson, CBO at Biovian, will be presenting and participating in a panel discussion at the Global Bioprocessing Summit in Berlin! The Global Bioprocessing Summit, taking place on November …
Junior Chamber International (JCI) Turku has recognized Biovian as the Turku Developer 2023. We are delighted and honored to announce that Biovian has received the Turku Developer 2023 award by JCI Turku, Finland on Friday, …
Biovian, a leading biopharmaceutical CDMO from Finland, uncovers the stonemasonry work of its new manufacturing facility, GeneCity. Located in a growing technology hub at Turku, Kupittaa, the state-of-the-art facility houses a blend of cutting-edge equipment …
Great news! There is a double chance to meet us on October 24-27, 2023! We extend a warm invitation to all industry experts, professionals, and partners to visit our booths at ESGCT Congress and CPHI …
We invite you to explore the recent article “Next Level Biopharmaceuticals” featured in the Business Focus Magazine’s latest issue. Business Focus Magazine interviewed Biovian’s CEO and co-founder Antti Nieminen about Biovian’s growth story and position …
We are delighted to tell you that Biovian will be participating in the Biotech Week Boston on September 18-21, 2023! You can meet our team at the concurrent BPI/Cell & Gene Therapy Manufacturing & Commercialization …
Biovian Oy, a leading contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals, announces a major investment of over €50 million to expand its manufacturing facility in Turku, Finland. The new facility will cover an …
